-
Company Insights
New![]()
Innovation and Patenting activity of Better Collective A/S Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Better Collective A/S Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
New![]()
Riverside Invt – Queensbridge Collective Mixed-Use Tower – North Carolina
Equip yourself with the essential tools needed to make informed and profitable decisions with our Riverside Invt – Queensbridge Collective Mixed-Use Tower – North Carolina report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to buy Acquire a thorough understanding of...
-
Company Insights
New![]()
Innovation and Patenting activity of Suofeiya Home Collection Co Ltd Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Suofeiya Home Collection Co Ltd Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report...
-
Analyst Opinions
New![]()
Australia Wealth Management – Market Sizing and Opportunities to 2027
Australia Wealth Management Report Overview Affluent individuals (including HNW individuals and mass affluents) collectively held the vast majority of onshore liquid assets, highlighting the country’s high level of wealth imbalance. The equities market recorded significant volatility resulting in a decline. Additionally, inflationary pressures and supply chain disruptions across 2022 and 2023 translated into more depressed financial markets, thus impacting investor sentiment. The Australia Wealth Management market research report will help to keep up to date with the Australian wealth management...
-
Thematic Analysis
New![]()
Internet of Things (IoT) in Media – Thematic Intelligence
Although it has been somewhat sidelined by artificial intelligence in the industry-especially after the launch of Chat-GPT in late 2022-IoT remains crucial for media. IoT use cases in the media industry include connecting devices and collecting user data to create more customized and engaging experiences, cut costs, and enhance the efficiency of operations. Forecasts suggest that IoT use in the sector will increase in the next four years, implying that the technology is here to stay.
-
Thematic Analysis
New![]()
Cybersecurity in Medical Devices – Thematic Intelligence
Cybersecurity remains a priority for enterprises The tech industry is experiencing significant upheaval. Big Tech has made mass layoffs to cut costs, and cybersecurity companies are not immune. However, while information technology (IT) budgets face scrutiny as companies cut discretionary spending, cybersecurity will remain a priority. Cyber risk is higher than ever, and the consequences of attacks are significant. According to Cybersecurity Ventures, global cybercrime will reach $10.5 trillion annually by 2025. Tackling this issue requires investment, and GlobalData forecasts...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Cell Therapy for Coronavirus Disease 2019 (COVID-19), Alopecia Areata and Type 1 Diabetes in Type 1 Diabetes (Juvenile Diabetes)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Cell Therapy For Coronavirus Disease 2019 (Covid-19), Alopecia Areata And Type 1 Diabetes in Type 1...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Inobrodib in Solid Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Inobrodib in Solid Tumor Drug Details:Inobrodib (CCS-1477) is under development for the treatment of solid tumors...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SND-002 in Metastatic Melanoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.SND-002 in Metastatic Melanoma Drug Details:SND-002 (Sentoclone) is under development for the treatment of malignant melanoma...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Inobrodib in Metastatic Breast Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Inobrodib in Metastatic Breast Cancer Drug Details:Inobrodib (CCS-1477) is under development for the treatment of solid...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.